These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11417 related articles for article (PubMed ID: 10422284)

  • 1. [PRAME protein expressed in leukemia cells as a target molecule for immunotherapy].
    Ikeda H; Matsushita M; Kawakami H
    Rinsho Ketsueki; 1999 Jun; 40(6):484-6. PubMed ID: 10422284
    [No Abstract]   [Full Text] [Related]  

  • 2. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
    Griffioen M; Kessler JH; Borghi M; van Soest RA; van der Minne CE; Nouta J; van der Burg SH; Medema JP; Schrier PI; Falkenburg JH; Osanto S; Melief CJ
    Clin Cancer Res; 2006 May; 12(10):3130-6. PubMed ID: 16707612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for melanoma.
    Komenaka I; Hoerig H; Kaufman HL
    Clin Dermatol; 2004; 22(3):251-65. PubMed ID: 15262312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma.
    Proto-Siqueira R; Figueiredo-Pontes LL; Panepucci RA; Garcia AB; Rizzatti EG; Nascimento FM; Ishikawa HC; Larson RE; Falcão RP; Simpson AJ; Gout I; Filonenko V; Rego EM; Zago MA
    Leuk Res; 2006 Nov; 30(11):1333-9. PubMed ID: 16620968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosomal aberrations in leukaemia cells may delete tumour target antigens of stem cell-based immunotherapy.
    Hambach L; Nijmeijer BA; Drabbels JJ; Falkenburg JH; Goulmy E
    Leukemia; 2006 Jul; 20(7):1298-300. PubMed ID: 16628185
    [No Abstract]   [Full Text] [Related]  

  • 6. Vaccines in leukemia.
    Lu S; Wieder E; Komanduri K; Ma Q; Molldrem JJ
    Adv Pharmacol; 2004; 51():255-70. PubMed ID: 15464913
    [No Abstract]   [Full Text] [Related]  

  • 7. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.
    Paydas S; Tanriverdi K; Yavuz S; Disel U; Baslamisli F; Burgut R
    Am J Hematol; 2005 Aug; 79(4):257-61. PubMed ID: 16044453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of melanoma: peptide mimics of a human high molecular weight-melanoma associated antigen.
    Wang X; Luo W; Ferrone S
    Medicina (B Aires); 2000; 60 Suppl 2():48-50. PubMed ID: 11188931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
    Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP
    Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer vaccines and immunotherapies: emerging perspectives.
    Henderson RA; Mossman S; Nairn N; Cheever MA
    Vaccine; 2005 Mar; 23(17-18):2359-62. PubMed ID: 15755628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary trials of clinical immunotherapy.
    Andrews GA; Congdon CC; Edwards CL; Gengozian N; Nelson B; Vodopick H
    Cancer Res; 1967 Dec; 27(12):2535-41. PubMed ID: 6082295
    [No Abstract]   [Full Text] [Related]  

  • 12. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?
    Campoli M; Ferrone S
    Expert Rev Vaccines; 2004 Apr; 3(2):171-87. PubMed ID: 15056043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer.
    Xu Y; Zou R; Wang J; Wang ZW; Zhu X
    Cell Prolif; 2020 Mar; 53(3):e12770. PubMed ID: 32022332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
    Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
    Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of melanoma.
    Chapman PB
    Cancer Chemother Biol Response Modif; 2002; 20():371-83. PubMed ID: 12703215
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
    Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
    Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.
    Greiner J; Schmitt M
    Eur J Haematol; 2008 Jun; 80(6):461-8. PubMed ID: 18284627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5T4 oncotrophoblast glycoprotein: janus molecule in life and a novel potential target against tumors.
    Zhao Y; Wang Y
    Cell Mol Immunol; 2007 Apr; 4(2):99-104. PubMed ID: 17484803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapy of acute leukemia (author's transl)].
    Ohno R; Kato Y
    Rinsho Ketsueki; 1980 Sep; 21(9):1324-7. PubMed ID: 6450292
    [No Abstract]   [Full Text] [Related]  

  • 20. Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma.
    Har-Noy M; Zeira M; Weiss L; Fingerut E; Or R; Slavin S
    Leuk Res; 2009 Apr; 33(4):525-38. PubMed ID: 18834631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 571.